Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib Dosing in Post-Osimertinib Lung Adenocarcinoma
NCT06394674Phase 2Recruiting
- Sponsor
- Changhai Hospital
- Start
- May 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of furmonertinib in lung adenocarcinoma (2 arms), sponsored by Changhai Hospital. Primary endpoint: Objective Response Rate at 12 months. Started May 2024; status: recruiting.
02
Drugs
furmonertinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT06394674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06394674.